Alternative Data for Caribou Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 17 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,692 | Sign up | Sign up | Sign up |
| X Followers | 6,600 | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 43 | Sign up | Sign up | Sign up |
| Linkedin Employees | 133 | Sign up | Sign up | Sign up |
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
| Price | $1.57 |
| Target Price | Sign up |
| Volume | 1,010,000 |
| Market Cap | $147M |
| Year Range | $1.05 - $2.84 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Medical Devices |
In the news
 |
Caribou Biosciences price target lowered by $2 at BofA, here's whyJanuary 6 - Thefly.com |
Genetic Engineering Tools - Global Market Opportunity and Forecast Report 2026-2031January 23 - GlobeNewswire |
|
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment TrendsJanuary 22 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 2.2M | 630,000 | 1.6M | -28M | -27M | -0.300 |
| Q2 '25 | 2.7M | 0 | 2.7M | -54M | -34M | -0.580 |
| Q1 '25 | 2.4M | 0 | 2.4M | -40M | -42M | -0.430 |
| Q4 '24 | 2.1M | 30M | -28M | -35M | -37M | -0.390 |
| Q3 '24 | 2M | 1.2M | 2M | -35M | -37M | -0.380 |
Insider Transactions View All
| Haurwitz Rachel E. filed to buy 3,369,395 shares at $1. March 17 '25 |
| MCCLUNG BARBARA G filed to sell 443,502 shares at $1.4. February 21 '25 |
| Kanner Steven filed to sell 431,556 shares at $1.4. February 21 '25 |
| Khan Ruhi Ahmad filed to sell 66,936 shares at $1.4. February 21 '25 |
| Ryali Sriram filed to buy 17,360 shares at $1.4. January 30 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Boston ScientificBSX |
$76.27 0% | 65 |
 |
Edwards LifesciencesEW |
$78.71 0% | 44 |
 |
Intuitive SurgicalISRG |
$488.15 0% | 54 |
 |
MedtronicMDT |
$102.9 0% | 60 |
 |
StrykerSYK |
$358.29 0% | 54 |
Read more about Caribou Biosciences (CRBU) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Caribou Biosciences
The Market Cap of Caribou Biosciences is $147M.
Currently, the price of one share of Caribou Biosciences stock is $1.57.
The CRBU stock price chart above provides a comprehensive visual representation of Caribou Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Caribou Biosciences shares. Our platform offers an up-to-date CRBU stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Caribou Biosciences (CRBU) does not offer dividends to its shareholders. Investors interested in Caribou Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Caribou Biosciences are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
